Physician profile
Peter Yang
NPI 1174183230
$457.88
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $195 · 2024: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $108.37 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $88.87 | 2023-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $37.66 | 2023-2024 | |
| Exact Sciences Corporation | $35.21 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $29.13 | 2023-2024 | Verquvo, Belsomra, Gardasil 9 |
| Axsome Therapeutics, INC. | $27.37 | 2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $21.19 | 2024 | Xarelto |
| Glaxosmithkline, LLC. | $19.20 | 2024 | Trelegy Ellipta, Arexvy |
| Ironwood Pharmaceuticals, INC | $18.50 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $15.76 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $15.56 | 2023 | Fasenra |
| Pfizer INC. | $14.28 | 2023 | |
| Azurity Pharmaceuticals, INC. | $14.00 | 2024 | Edarbi |
| Idorsia Pharmaceuticals US INC | $12.78 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.